腎と骨代謝 Vol.19 No.2(7)


特集名 ステロイドと骨代謝
題名 関節リウマチにおけるステロイド性骨粗鬆症
発刊年月 2006年 04月
著者 中山 久徳 独立行政法人国立病院機構相模原病院リウマチ科
【 要旨 】 関節リウマチ (RA) 患者では,骨粗鬆症と椎体骨折の頻度が高い.これらは重大でかつ難治性の合併症と認識されるべきである.RAにおける,骨粗鬆症の成因は,炎症性疾患であることや身体活動性低下など多岐にわたるがステロイド (グルココルチコイド) 投与の影響も大きい.ステロイドを投与されたRA患者では骨密度がいっそう低下し,骨折のリスクも高まる.ビスフォスフォネート (BP) はRA患者においても骨密度増加作用を認め,新規椎体骨折発生を抑制する有効な薬剤である.したがって,RA患者,とくにステロイド投与を受ける患者では早期からBPを中心とした,骨粗鬆症予防および治療が望まれる.
Theme Glucocorticoid-induced osteoporosis and bone metabolism
Title Clinical features and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients
Author Hisanori Nakayama Department of Rheumatology, National Hospital Organization, Sagamihara Hospital
[ Summary ] Generalized osteoporosis and vertebral fractures are frequently observed in patients with rheumatoid arthritis (RA) along with deterioration in their ADL and QOL. This is due to a combination of several factors, in particular disease progression, impaired mobility and medications, especially use of glucocorticoids (GC). Bone loss results in an increased risk of fractures and associated morbidity and mortality. The frequency of osteoporosis among RA patients was 53.3 %. That for vertebral fractures was 19.3 %. These were much higher rates than those for the general population. The occurrence of osteoporosis and vertebral fractures was significantly higher in RA patients receiving GCs than in those not receiving them. A negative relationship was shown between bone mineral density, the cumulative dosages of GC and the duration of GC treatment. According to our prospective fracture intervention trial, bisphosphonates were effective for treatment of osteoporosis and prevention of vertebral fractures in RA patients.
戻る